Category: eClinical Systems
Traditional on-site monitoring spends similar effort on every site, whether or not the data warrants it — while real signals hide in the aggregate.
Classic trial monitoring sends monitors to every site on a similar schedule to verify data against source records — expensive, travel-heavy, and indifferent to where the actual risk sits. Regulatory guidance has moved toward risk-based approaches, and centralized statistical monitoring is the enabling capability: analyzing the accumulating trial data across all sites to find the ones whose data looks wrong, so monitoring effort follows evidence instead of the calendar.
Centralized monitoring tools analyze the trial's accumulating data across every site at once, looking for statistical signatures that on-site review can't see: distributions that differ from the rest of the study, implausibly regular measurements, unusual patterns in timing or completeness, and drift that suggests a process problem rather than random variation. The output is a ranked view of site-level risk with the underlying evidence, which lets monitoring leads direct visits, remote checks, and retraining toward the sites whose data justifies the attention. The judgment stays human: a statistical flag is a reason to look, not a conclusion about a site's conduct. Central monitors and clinical operations decide what a signal means and what action follows, and documented risk-based monitoring processes — supported by ICH E6 guidance on quality management — frame how those decisions are recorded. The tooling changes what is visible, not who is accountable.
Explainability of flags is the working requirement: a monitor acting on a signal needs to see which data drove it and why it is unusual, in terms a clinical operations team can carry into a site conversation. Probe the false-positive burden honestly — every flag consumes central-monitor time, and a tool that cries wolf gets ignored. Ask vendors to run their analytics retrospectively on one of your completed studies and compare the flagged sites against the issues your team actually found and documented. Operationally, examine how the tool fits your monitoring plan and documentation: how risk indicators are configured per study, how review decisions and their rationale are captured for inspection, and how the analytics connect to your data-capture platform without a parallel data-entry burden.
A retrospective pilot on a completed study is the standard entry: run the analytics over the final dataset and compare flagged sites against the monitoring findings, protocol deviations, and audit outcomes the team already knows. That measures whether the signals point at real problems on verifiable ground truth. Teams that see meaningful correlation typically introduce the tooling on a live study alongside the existing monitoring plan first, shifting visit frequency only after the signals have earned trust.
It is the analysis of a trial's accumulating data across all sites to identify the ones whose data looks statistically unusual — unexpected distributions, implausible regularity, timing anomalies — so monitoring effort can be directed where the evidence points rather than spread evenly by calendar.
Regulatory guidance, including ICH E6, explicitly supports risk-based, quality-managed approaches to monitoring rather than mandating uniform full source verification. What inspectors look for is a documented, justified monitoring plan and evidence that signals were reviewed and acted on — the discipline matters as much as the analytics.
No — it redirects them. Sites with clean, plausible data can be monitored more remotely and less frequently, while sites with genuine signals get more attention, sooner. On-site work remains part of the plan; the change is that its allocation follows evidence.
Only that the site's data is unusual enough to warrant a look. Legitimate explanations — a different patient population, an equipment difference, a local practice — are common, and distinguishing them from real quality problems is exactly the judgment central monitors and clinical operations are there to make.
CluePoints was recognized with a 2025 Scrip Award, cited as a risk-based quality management and AI leader in clinical development.
Vendor: CluePoints · press release (CluePoints (PR Newswire)) · 2025-12-12